Medical News / Directly from AAO 2021: Reduced Retinal Fluid Linked to Better nAMD Visual Improvements

Improved best corrected visual acuity (BCVA) gains from anti-VEGF therapy are associated with instances of lesser post-loading retinal fluid in patients with neovascular age-related macular degeneration (AMD), according to new findings. In new post hoc analysis data from the HAWK and HARRIER trials, presented at the American Academy of Ophthalmology (AAO) 2021 Meeting in New Orleans, a team of investigators observed that greater BCVA gains from anti-VEGF treatment were more frequent among patients with a greater rate of fluid-free visits through week 96 of the original phase 3 trials. Source: MDMAg. To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

According to new phase 3 data presented at the American Academy of Ophthalmology 2021 Meeting, brolucizumab ... read more
In an interview with HCPLive, Veeral Sheth, MD, Director of Clinical Trials, University Retina, discussed the ... read more
Access to US ophthalmology clinical trial sites may differ by region, according to new study findings ... read more
Although there are questions on the rationale behind step therapy, particularly for neovascular (wet) age-related macular ... read more